About 591,291 results

New Kidney Cancer Research From the ASCO20 Virtual Scientific Program Demonstrates an Exciting, Evolving Field

Jun 24th, 2020 - There used to be a paucity of options for managing advanced renal cell cancer (RCC) with a high toxicity profile including traditional chemotherapy, interferon, and interleukins. With the advent of tyrosine kinase inhibitors (TKIs) in 2007 followed by immunotherapy over the past few years, a paradigm shift emerged in managing this increasingly prevalent disease with its associated high morbidit...

Researchers gain insight into factors influencing immunotherapy response in kidney cancer

Jul 9th, 2020 - Tumor mutational burden is considered a hallmark indicator of a tumor’s potential for response to immunotherapy. PD-1 checkpoint inhibitors such as pembrolizumab (Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb) have been shown to be more effective in treating tumors with high mutational burden. However, despite having only a moderate number of mutations, advanced clear cell ren...

Update Alert 2: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults

COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers

Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors
https://journals.lww.com/ajg/Documents/AJG-20-1811_R1(PUBLISH AS WEBPART).pdf

Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China

Antihypertensive drugs and risk of COVID-19?
The Lancet Respiratory Medicine;

Mar 25th, 2020 - Lei Fang and colleagues1 suggest that clinicians should consider withholding angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) because of a potential increased risk of worse clinical outcomes in patients with coronavirus disease 2019 (COVID-19), and they suggest calcium channel blockers as an alternative. The hypothesis behind this suggestion is that the e...

The Potential Therapeutic Role of Proton Pump Inhibitors in COVID-19: Hypotheses Based on Existing Evidences

Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?

Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID‐19: coincidence or underestimated risk factor?

Study Finds Patients With Lung Cancer Infected With COVID-19 Are at High Risk for Hospitalization

May 28th, 2020 - Data from the global TERAVOLT Consortium, which is investigating the impact of COVID-19 infection on patients with thoracic cancers, have found that these patients are at high risk for hospitalization and death. Prior use of chemotherapy was associated with an increased risk of mortality, as was the use of steroids or anticoagulants. Prior administration of immunotherapy and chemoimmunotherapy ...

Addition of Ublituximab to Ibrutinib Appears Safe and Effective for Patients With High-Risk Chronic Lymphocytic Leukemia

May 12th, 2020 - Although chronic lymphocytic leukemia (CLL) has a relatively high 5-year survival rate (85% for people age 20 and older), effective treatments for advanced disease are still needed. Use of combination or monotherapy Bruton’s tyrosine kinase (BTK) inhibitors has shown promise for people with CLL, with the BTK inhibitor ibrutinib now considered a standard of care for patients of any age. However,...

Combination Immunotherapy Could Be a Potential Treatment Option for Rare Gynecologic Cancers, Pending Randomized Trial Validation

May 12th, 2020 - The novel combination of immune checkpoint inhibitors ipilimumab and nivolumab may offer patients with rare gynecologic neoplasms the opportunity for improved outcomes, according to a new study (Abstract 6091) that will be presented during the ASCO20 Virtual Scientific Program.

PARP Inhibition Improves Outcomes in Patients With BRCA-Mutated Ovarian Cancer

May 28th, 2020 - David O'Malley, MD, professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine, and director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–The James, discusses the role of PARP inhibitors in the treatment landscape of ovarian cancer.

Expanding the role of PARP inhibitors in breast cancer

May 30th, 2020 - For patients with BRCA-like triple-negative breast cancer (TNBC), adding veliparib to cisplatin chemotherapy may extend survival, based on results from the phase 3 SWOG S1416 trial.

Autoantibodies May Predict Disease Response in Metastasized Melanoma Treated With Checkpoint Inhibitors

May 29th, 2020 - There is a diverse and broad autoantibody response to tumor and autoimmune disease antigens in melanoma treated with checkpoint inhibitors (CPIs). Results from a recent study presented during the ASCO20 Virtual Scientific Meeting show that some of those autoantibodies correlate to clinical outcomes and immune-related adverse events (irAEs; Abstract 10011).

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19
The New England Journal of Medicine;

Coronavirus disease 2019 (Covid-19) may disproportionately affect people with cardiovascular disease. Concern has been aroused regarding a potential harmful effect of angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) in this clinical context.

WFH Guidelines for the Management of Hemophilia, 3rd edition

Aug 2nd, 2020 - This new edition of the World Federation of Hemophilia (WFH) guidelines for the management of hemophilia comes at an exciting time in the evolution of the diagnosis and treatment of this condition. Since the publication of the second edition in 2012, tremendous advances have been made in several aspects of the management of hemophilia. These include genetic assessment as well as therapy with ma...

The Hypotensive Role of Acupuncture in Hypertension: Clinical Study and Mechanistic Study

As a component of traditional Chinese medicine (TCM), acupuncture has the potential to lower blood pressure (BP) in patients with hypertension. Emerging evidence indicates that the acupuncture-induced inhibition of high BP occurs through the activation of the pathway in the afferent, central, and efferent pathways. An increasing number of studies have demonstrated that acupuncture not only acti...

Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches